,36 Consistent with these observations, we recently used SplitFusion and further demonstrated that intratumoral EML4::ALK isoforms may have different sensitivities to ALK inhibitors and may predict the efficacy of targeted therapy in ALK-rearranged lung cancer.37 The gene discussed is EML4; the disease is lung carcinoma.